Drug Trial Radar · NCT05337878
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants
Last checked: Nov 19, 2026Latest source record: Apr 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Oct 15, 2018
Primary completion
Dec 18, 2019
Study completion Dec 18, 2019
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Apr 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of Pelacarsen (ISIS 681257) in healthy Japanese participants.
Conditions
- Healthy Participants
Interventions
PlaceboDrug
Pelacarsen-matching placebo administered by SC injection.
PelacarsenDrug
Pelacarsen administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD: Percentage of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Evaluation ParametersTime frame: Up to Day 90
- SAD: Percentage of Participants With Adverse EventsTime frame: Up to Day 90
- SAD: Percentage of Participants With Serious Adverse EventsTime frame: Up to Day 90
- MAD: Percentage of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Evaluation ParametersTime frame: Up to Day 204
- MAD: Percentage of Participants With Adverse EventsTime frame: Up to Day 204
- MAD: Percentage of Participants With Serious Adverse EventsTime frame: Up to Day 204
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.